in the red, page-20

... It just may be that the underlying problem is that the ' immunotherapy space ' is staring to become a little more crowded ... like it or not

look at Dendreon and its recent share price trashing ... and all the rumblings about alternative ' pills ' ... and its expensive set up ...

.. PRR has the technology and the product ... and will have to regroup and press on with new found vigour and cost structures ... with haste .... if it wishes to stave off any real challengers or alternatives to it's patented product ...

.. you would assume that the phase 111 trials in the biospace are quite ambitious ... and to recruit some 800 patients into a blind program is by no means a fast process..... and hence it's worldwide trial in search of ' recruits' ....

... the trouble with connecting with DNDN was flawed from the start ... great with the Promos when DNDN was booming ... but in hindsight an error .... it will forever difficult to distance itself .. and the work is cut out for Prima to do so .....

... pass me a beer